Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

詳細情報 詳細情報について

• CRID

  1360857596857449344

• DOI

  10.1093/annonc/mdz399

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753420325540?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753420325540?httpAccept=text/plain

  http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz399/30150398/mdz399.pdf

  http://academic.oup.com/annonc/article-pdf/30/12/1978/31637903/mdz399.pdf

• データソース種別

  • Crossref